Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002150 · ClinicalTrials.gov registry record · Phase 2

A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients

A Phase 2 study of HIV Infections, sponsored by Hoechst Marion Roussel.

Completed
Registry status
Phase 2
Development phase
200
Enrollment target
20
Study locations

NCT00002150: Completed Phase 2 study of HIV Infections, sponsored by Hoechst Marion Roussel.

NCT00002150 is a Phase 2 study of HIV Infections that has completed, run by Hoechst Marion Roussel. The registered enrollment target is 200 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002150, a Phase 2 study of HIV Infections, has completed, sponsored by Hoechst Marion Roussel.

COMPLETED
Registry status
Phase 2
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

To characterize the safety and efficacy of fixed doses of MDL 28,574A administered alone and in combination with zidovudine ( AZT ) in patients with asymptomatic or mildly symptomatic HIV infection. To examine the demographic effects on population pharmacokinetics and pharmacodynamics of MDL 28,574A alone and in combination with AZT.

Conditions Studied

HIV Infections

Interventions

  • DRUG Celgosivir hydrochloride

Study Locations (20)

Florida

  • Community Research Initiative of South Florida - Coral Gables
  • Independent Investigator - Fort Lauderdale
  • North Broward Hosp District - Fort Lauderdale
  • Clinical Research Ctr - Sarasota
  • Independent Investigator - Vero Beach

California

  • California Clinical Trials Med Group - Beverly Hills
  • Southwest Community Based AIDS Treatment Group - COMBAT - Los Angeles
  • UCSF - San Francisco Gen Hosp - San Francisco

New York

  • Community Health Network - Rochester
  • SUNY / Health Sciences Ctr at Stony Brook - Stony Brook

Alabama

  • Clinical Investigations Health Services - Mobile

District of Columbia

  • George Washington Univ / Hershey Med Ctr - Washington D.C.

Illinois

  • Ctr for Special Immunology - Chicago

Indiana

  • Indiana Univ Hosp - Indianapolis

Kansas

  • Univ of Kansas School of Medicine - Wichita

Trial Details

FieldValue
Enrollment Target 200 participants
Phase Phase 2

Sponsor

Hoechst Marion Roussel

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00002150

The ClinicalTrials.gov registry entry for NCT00002150 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower). The listed sponsor is Hoechst Marion Roussel, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Celgosivir hydrochloride is the first listed.

NCT00002150 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, New York.

Frequently Asked Questions

What is clinical trial NCT00002150 about?

NCT00002150 is a clinical study titled "A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients". To characterize the safety and efficacy of fixed doses of MDL 28,574A administered alone and in combination with zidovudine ( AZT ) in patients with asymptomatic or mildly symptomatic HIV infection. To examine the demographic effects on population pharmacokinetics and pharmacodynamics of MDL 28,574A...

What is the current status of trial NCT00002150?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants.

What conditions does trial NCT00002150 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002150?

The interventions under investigation include: Celgosivir hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00002150?

This trial is sponsored by Hoechst Marion Roussel, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002150 being conducted?

This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.